A new trading day began on Friday, with Stereotaxis Inc (AMEX: STXS) down -8.90% from the previous day of trading, before settling in for the closing price of $3.37. STXS’s price has ranged from $1.54 to $3.59 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -25.52% over the past five years. Meanwhile, its annual earnings per share averaged 23.33%. With a float of $74.37 million, this company’s outstanding shares have now reached $86.00 million.
Stereotaxis Inc (STXS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Stereotaxis Inc is 18.27%, while institutional ownership is 45.52%. The most recent insider transaction that took place on Mar 10 ’25, was worth 68,780. In this transaction Director of this company bought 38,000 shares at a rate of $1.81, taking the stock ownership to the 87,299 shares. Before that another transaction happened on Mar 06 ’25, when Company’s Director bought 23,299 for $1.81, making the entire transaction worth $42,171. This insider now owns 49,066 shares in total.
Stereotaxis Inc (STXS) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.08 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 48.91% during the next five years compared to -25.52% drop over the previous five years of trading.
Stereotaxis Inc (AMEX: STXS) Trading Performance Indicators
Here are Stereotaxis Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.16 in one year’s time.
